Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Blood

• Publication date

  2004-11-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2006-04-015149PMID 17032924PMCID PMC1785138
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthetic Smac peptide enhances the effect of etoposide-induced apoptosis in human glioblastoma cell lines

  2006cited by this paper
• Development of Peptidomimetics Targeting IAPs

  2006cited by this paper
• Non-peptidic small molecule inhibitors of XIAP.

  2005cited by this paper
• Proteasome inhibition in multiple myeloma: therapeutic implication.

  2005cited by this paper
• Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics.

  2005cited by this paper
• A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

  2005cited by this paper
• Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

  2004cited by this paper
• A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death.

  2004influential reference
• A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death

  2004cited by this paper
• Aureoverticillactam, a novel 22-atom macrocyclic lactam from the marine actinomycete Streptomyces aureoverticillatus.

  2004cited by this paper
• Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.

  2004cited by this paper
• Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.

  2004cited by this paper
• Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide.

  2003cited by this paper
• Fibroblast Growth Factor 2-Mediated Translational Control of IAPs Blocks Mitochondrial Release of Smac/DIABLO and Apoptosis in Small Cell Lung Cancer Cells

  2003cited by this paper
• Apoptosis regulators.

  2003cited by this paper
• Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications

  2003cited by this paper
• Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia.

  2003cited by this paper
• Elevated expression of inhibitor of apoptosis proteins in prostate cancer.

  2003cited by this paper
• A JNK-dependent pathway is required for TNFalpha-induced apoptosis.

  2003cited by this paper
• Moving disease biology from the lab to the clinic

  2003cited by this paper
• Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.

  2003cited by this paper
• Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation*

  2002cited by this paper
• Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.

  2002cited by this paper
• Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

  2002cited by this paper
• Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.

  2002cited by this paper
• Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis.

  2002cited by this paper
• Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Can

  2002cited by this paper
• Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

  2002cited by this paper
• NF-kappa B as a therapeutic target in multiple myeloma.

  2002cited by this paper
• Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

  2002cited by this paper
• Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ *

  2002cited by this paper
• Molecular sequelae of proteasome inhibition in human multiple myeloma cells

  2002cited by this paper
• 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.

  2002cited by this paper
• NF-κB as a Therapeutic Target in Multiple Myeloma*

  2002cited by this paper
• Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.

  2002cited by this paper
• Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils : up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia

  2002cited by this paper
• Molecular mechanisms of novel therapeutic approaches for multiple myeloma

  2002cited by this paper
• The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications

  2001cited by this paper
• A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death.

  2001cited by this paper
• The expanding role of mitochondria in apoptosis.

  2001cited by this paper
• Vascular Endothelial Growth Factor (VEGF) -induced migration of Multiple Myeloma cells is associated with ββββ 1-integrin- and PI3-kinase- dependent PKC αααα activation

  2001cited by this paper
• Apaf-1/Cytochrome c-independent and Smac-dependent Induction of Apoptosis in Multiple Myeloma (MM) Cells*

  2001cited by this paper
• The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.

  2001cited by this paper
• Apoptosis‐associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl‐2

  2001cited by this paper
• Endonuclease G is an apoptotic DNase when released from mitochondria

  2001cited by this paper
• A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis

  2001cited by this paper
• TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

  2001cited by this paper
• Structural basis of IAP recognition by Smac/DIABLO

  2000cited by this paper
• Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain

  2000cited by this paper
• Structural and biochemical basis of apoptotic activation by Smac/DIABLO

  2000cited by this paper
• Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins.

  2000cited by this paper
• SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.

  2000cited by this paper
• Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition.

  2000cited by this paper
• Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.

  2000cited by this paper
• Mitochondrial control of cell death

  2000cited by this paper
• IAP family proteins--suppressors of apoptosis.

  1999cited by this paper
• Apoptosis: checkpoint at the mitochondrial frontier.

  1999cited by this paper
• Molecular characterization of mitochondrial apoptosis-inducing factor

  1999cited by this paper
• Caspases: enemies within.

  1998cited by this paper
• Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.

  1998cited by this paper
• Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked

  1997cited by this paper
• A lively meeting on a deathly topic.

  1997cited by this paper
• Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.

  1997cited by this paper
• Cytochrome c-dependent and -independent Induction of Apoptosis in Multiple Myeloma Cells*

  1997cited by this paper
• A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth.

  1997cited by this paper
• Multiple myeloma cells are protected against dexamethasone‐induced apoptosis by insulin‐like growth factors

  1997cited by this paper
• Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.

  1996cited by this paper
• Interleukin-6 prevents dexamethasone-induced myeloma cell death.

  1994cited by this paper
• Chromatin condensation during apoptosis is accompanied by degradation of lamin A+B, without enhanced activation of cdc2 kinase

  1994cited by this paper
• Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.

  1993cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Cell death: the significance of apoptosis.

  1980cited by this paper

• Bio-mimetic strategies to re-activate apoptotic cell death for cancer treatments

  2024cites this paper
• Mitochondrial dysfunction and drug targets in multiple myeloma

  2023cites this paper
• Cancer and apoptosis

  2022cites this paper
• Molecular mechanisms of cell death

  2022cites this paper
• Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma

  2021cites this paper
• Design, Synthesis, and Biological Evaluation of Imidazopyrazinone Derivatives as Antagonists of Inhibitor of Apoptosis Proteins (IAPs)

  2021cites this paper
• The Mitochondrion as an Emerging Therapeutic Target in Cancer.

  2020cites this paper
• Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B‐cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis

  2020cites this paper
• SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases

  2020cites this paper
• Development of a hybrid nanocarrier-recognizing tumor vasculature and penetrating the BBB for glioblastoma multi-targeting therapy.

  2019cites this paper
• SMAC mimetics as potential cancer therapeutics in myeloid malignancies

  2019cites this paper
• Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams†

  2019cites this paper
• Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives.

  2019cites this paper
• The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

  2019cites this paper
• Synthesis and anticancer activity of conformationally constrained Smac mimetics containing pseudo β turns

  2018cites this paper
• Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer

  2018cites this paper
• Smac mimetics as novel promising modulators of apoptosis in the treatment of breast cancer

  2018cites this paper
• Investigating the adverse effects of novel tumour-specific IAP antagonists

  2017cites this paper
• Smac Mimetics to Therapeutically Target IAP Proteins in Cancer.

  2017cites this paper
• Therapeutic opportunities based on caspase modulation.

  2017cites this paper
• Biological determinants of radioresistance and their remediation in pancreatic cancer.

  2017cites this paper
• L-Tetrahydropalmatine Induces Apoptosis in EU-4 Leukemia Cells by Down-Regulating X-Linked Inhibitor of Apoptosis Protein and Increases the Sensitivity Towards Doxorubicin.

  2017cites this paper
• NOD2 and bacterial recognition as therapeutic targets for Crohn’s disease

  2017cites this paper
• IAPs and Resistance to Death Receptors in Cancer

  2017cites this paper
• Post-translational modification profiling – A novel tool for mapping the protein modification landscape in cancer

  2016cites this paper
• IAP antagonists induce anti-tumor immunity in multiple myeloma

  2016cites this paper
• Smac mimetic‑induced caspase‑independent necroptosis requires RIP1 in breast cancer.

  2016cites this paper
• ACTIVITY OF MONOMERIC SECOND MITOCHONDRIAL ACTIVATOR OF CASPASES (SMAC) MIMETIC COMPOUNDS ON HUMAN FIBROBLAST-LIKE SYNOVIOCYTES FROM RHEUMATOID ARTHRITIS PATIENTS

  2016cites this paper
• The SMAC mimetic BV6 induces cell death and sensitizes different cell lines to TNF-α and TRAIL-induced apoptosis

  2016cites this paper
• New Frontiers in Cancer Chemotherapy — Targeting Cell Death Pathways

  2016cites this paper
• Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma

  2016cites this paper
• Engineering Novel TNFα-armed Oncolytic Viruses for Combination Immunotherapy with SMAC Mimetics

  2016cites this paper
• Blockade of Inhibitors of Apoptosis Proteins in Combination with Conventional Chemotherapy Leads to Synergistic Antitumor Activity in Medulloblastoma and Cancer Stem-Like Cells

  2016cites this paper
• Novel SMAC Mimetics as Peptide-based Small Molecule Inhibitors of IAPs to Induce Apoptosis in Cancer Cells

  2015cites this paper
• A Time to Kill: Targeting Apoptosis in Cancer

  2015cites this paper
• Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia

  2015cites this paper
• Cloaked in ubiquitin, a killer hides in plain sight: the molecular regulation of RIPK1

  2015cites this paper
• Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment

  2015cites this paper
• Smac mimetics as IAP antagonists.

  2015cites this paper
• Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications.

  2015cites this paper
• Novel strategies to target the ubiquitin proteasome system in multiple myeloma

  2015cites this paper
• Differential Roles of the TRAF3 Adapter Protein in Adipogenesis and Glucose Metabolism

  2015cites this paper
• IAP Family of Proteins as Therapeutic Targets for Acute Myeloid Leukemia

  2015cites this paper
• Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport.

  2015cites this paper
• Targeting the inhibitor of Apoptosis Protein BIR3 binding domains.

  2014cites this paper
• Filename Chapter 2: Smac/DIABLO release from the mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation Version unknown

  2014cites this paper
• Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

  2014cites this paper
• Targeting the E3 ubiquitin ligases, Inhibitor of Apoptosis Protein and Anaphase Promoting Complex/Cyclosome, in multiple myeloma

  2014cites this paper
• Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma

  2014cites this paper
• Small-molecule SMAC mimetics as new cancer therapeutics.

  2014cites this paper
• Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities

  2014cites this paper
• Antagonists of IAP proteins: novel anti-tumor agents.

  2014cites this paper
• Inhibitors of apoptosis proteins (IAPs) are required for effective T-cell expansion/survival during antiviral immunity in mice.

  2014cites this paper
• Molecular Pathways Molecular Pathways : Targeting Death Receptors and Smac Mimetics

  2014cites this paper
• Berberine Induces Apoptosis in p53-Null Leukemia Cells by Down-Regulating XIAP at the Post-Transcriptional Level

  2013cites this paper
• IAP proteins as targets for drug development in oncology

  2013cites this paper
• Smac Mimetics in Combination with TRAIL Selectively Target Cancer Stem Cells in Nasopharyngeal Carcinoma

  2013cites this paper
• Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy

  2013cites this paper
• Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I' mode

  2013cites this paper
• RIP2 activity in inflammatory disease and implications for novel therapeutics

  2013cites this paper
• Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

  2013cites this paper
• BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

  2013cites this paper
• Human Cancer Resistance to Trail-Apoptotic Pathway-Targeted Therapies

  2013cites this paper
• Antiapoptotic Proteins in Human Macrophage Survival, Differentiation, Innate Immunity and Protection from HIV-induced Apoptosis

  2013cites this paper
• Cytokines and Signal Transduction in Multiple Myeloma

  2013cites this paper
• Critical Role for Antiapoptotic Bcl-xL and Mcl-1 in Human Macrophage Survival and Cellular IAP1/2 (cIAP1/2) in Resistance to HIV-Vpr-induced Apoptosis*

  2012cites this paper
• The microenvironment and treatment resistance in chronic lymphocytic leukemia

  2012cites this paper
• Protein-Protein Interactions as Drug Targets

  2012cites this paper
• MITOCHONDRIA : INSIGHT TARGET OF DRUG DEVELOPMENT IN CANCER CELLS

  2012cites this paper
• Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-α-independent apoptosis.

  2012cites this paper
• A Small Molecule SMAC Mimic LBW242 Potentiates TRAIL- and Anticancer Drug-Mediated Cell Death of Ovarian Cancer Cells

  2012cites this paper
• Ubiquitination and phosphorylation in the regulation of NOD2 signaling and NOD2-mediated disease.

  2012cites this paper
• Discovery of aminopiperidine-based Smac mimetics as IAP antagonists.

  2012cites this paper
• Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma

  2012cites this paper
• Targeting IAP proteins for therapeutic intervention in cancer

  2012cites this paper
• Primary CLL cells are resistant to cellular inhibitor apoptosis protein ( cIAP ) antagonists

  2012cites this paper
• Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma

  2012cites this paper
• Targeting Inhibitors of Apoptosis Proteins (IAPs) For New Breast Cancer Therapeutics

  2012cites this paper
• Chapter 3 - Deep-Sea Hydrothermal Vents as a New Source of Drug Discovery

  2012cites this paper
• Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis

  2012cites this paper
• Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies

  2012cites this paper
• Characterisation of TRAIL Receptor Signalling To Apoptosis in Pre-clinical Models of Breast Cancer

  2011cites this paper
• A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.

  2011cites this paper
• Role of Smac in Determining the Chemotherapeutic Response of Esophageal Squamous Cell Carcinoma

  2011influential citation
• Inhibitor of apoptosis (IAP) proteins in regulation of inflammation and innate immunity.

  2011cites this paper
• Solid-phase synthesis of an apoptosis-inducing tetrapeptide mimicking the Smac protein

  2011cites this paper
• Ethanol extract of Hedyotis diffusa willd. induction of apoptosis via PI3K/Akt and XIAP pathways in human leukemic THP-1 cells

  2011cites this paper
• Screening multicomponent reactions for X-linked inhibitor of apoptosis-baculoviral inhibitor of apoptosis protein repeats domain binder.

  2011cites this paper
• The effect of feeding frequency on growth performance and body composition in juvenile rainbow trout ( Oncorhynchus mykiss ) reared in cold seawater

  2011cites this paper
• Role of Bcl-2 family proteins and caspases in the regulation of apoptosis

  2011cites this paper
• Jolkinolide B from Euphorbia fischeriana Steud induces apoptosis in human leukemic U937 cells through PI3K/Akt and XIAP pathways

  2011cites this paper
• Cancer Therapy : Preclinical Role of Smac in Determining the Chemotherapeutic Response of Esophageal Squamous Cell Carcinoma

  2011cites this paper
• PR‐924, a selective inhibitor of the immunoproteasome subunit LMP‐7, blocks multiple myeloma cell growth both in vitro and in vivo

  2011cites this paper
• Targeting IAPs as an approach to anti-cancer therapy.

  2011cites this paper
• The Discovery and Development of Smac Mimetics—Small-Molecule Antagonists of the Inhibitor of Apoptosis Proteins

  2011cites this paper
• Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies.

  2011cites this paper
• Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.

  2011cites this paper
• The kinase NIK as a therapeutic target in multiple myeloma

  2011cites this paper
• Role of RNA Interference in Understanding the Molecular Basis of Cancer

  2010cites this paper
• Small-molecule pan-IAP antagonists: a patent review

  2010cites this paper